Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 62 results for botulinum a toxin

  1. Assessing motility of the gastrointestinal tract using a wireless capsule (IPG502)

    Evidence-based recommendations on assessing motility of the gastrointestinal tract using a wireless capsule. This involves swallowing a capsule that sends bowel information as it passes through the digestive system.

  2. Needle and syringe programmes (PH52)

    This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.

  3. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  4. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  5. Urinary incontinence in women (QS77)

    This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.

  6. Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)

    This evidence summary has been replaced by NICE guideline CG171.

  7. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

  8. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.

  9. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  10. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  11. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  12. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (IPG487)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.

  13. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  14. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

  15. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.